U.S. health regulators on Wednesday sent warning letters to 18 websites selling counterfeit or unapproved versions of Botox ...
The U.S. FDA approved a pricey rare disease drug in September despite findings by its data reviewers that the treatment, ...
D r. George Tidmarsh, the FDA drug regulator who was placed on leave and complained of a “toxic” work environment in an ...
George Tidmarsh, the newly installed director of the FDA’s Center for Drug Evaluation and Research, was placed on leave ...
In any review of mifepristone, the FDA will now have to grapple with Judge Otake’s conclusion that the 2023 REMS decision for ...
The director of the U.S. Food and Drug Administration’s Center for Drug Evaluation and Research, George Tidmarsh, resigned on Sunday amid serious concerns about his personal conduct, a Department of ...
Developers of biosimilars -- medicines that are near-identical copies of biologic drugs -- will no longer be required to conduct clinical trials to prove effectiveness.
Dr. George Tidmarsh, the FDA's top drug regulator, was placed on leave amid controversy over the drug approval process and a ...
FDA CDER Director George Tidmarsh resigns over controversy involving Aurinia Pharma board chair and lupus drug criticism. Read more here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback